SAVA Quote, Financials, Valuation and Earnings

BridgeBio Pharma has a net margin of -- compared to Cassava Sciences's net margin of -5931.19%. Cassava Sciences's return on equity of -- beat BridgeBio Pharma's return on equity of --.

Cassava Sciences has a consensus price target of --, signalling upside risk potential of 4815.25%. On the other hand BridgeBio Pharma has an analysts' consensus of $48.56 which suggests that it could grow by 83.28%. Given that Cassava Sciences has higher upside potential than BridgeBio Pharma, analysts believe Cassava Sciences is more attractive than BridgeBio Pharma.

Cassava Sciences has a beta of -0.856, which suggesting that the stock is 185.551% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.079, suggesting its more volatile than the S&P 500 by 7.928%.

Cassava Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

Cassava Sciences quarterly revenues are --, which are smaller than BridgeBio Pharma quarterly revenues of $2.7M. Cassava Sciences's net income of -$27.9M is higher than BridgeBio Pharma's net income of -$162M. Notably, Cassava Sciences's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences is 2.59x versus 22.18x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Bristol-Myers Squibb has a net margin of -- compared to Cassava Sciences's net margin of 10.18%. Cassava Sciences's return on equity of -- beat Bristol-Myers Squibb's return on equity of -33.18%.

Cassava Sciences has a consensus price target of --, signalling upside risk potential of 4815.25%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $60.91 which suggests that it could grow by 6.25%. Given that Cassava Sciences has higher upside potential than Bristol-Myers Squibb, analysts believe Cassava Sciences is more attractive than Bristol-Myers Squibb.

Cassava Sciences has a beta of -0.856, which suggesting that the stock is 185.551% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.454, suggesting its less volatile than the S&P 500 by 54.628%.

Cassava Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 4.19% to investors and pays a quarterly dividend of $0.60 per share. Cassava Sciences pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out 59.12% of its earnings as a dividend. Bristol-Myers Squibb's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cassava Sciences quarterly revenues are --, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.9B. Cassava Sciences's net income of -$27.9M is lower than Bristol-Myers Squibb's net income of $1.2B. Notably, Cassava Sciences's price-to-earnings ratio is -- while Bristol-Myers Squibb's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences is 2.59x versus 2.45x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

EyePoint Pharmaceuticals has a net margin of -- compared to Cassava Sciences's net margin of -278.99%. Cassava Sciences's return on equity of -- beat EyePoint Pharmaceuticals's return on equity of -50.67%.

Cassava Sciences has a consensus price target of --, signalling upside risk potential of 4815.25%. On the other hand EyePoint Pharmaceuticals has an analysts' consensus of $33.45 which suggests that it could grow by 369.87%. Given that Cassava Sciences has higher upside potential than EyePoint Pharmaceuticals, analysts believe Cassava Sciences is more attractive than EyePoint Pharmaceuticals.

Cassava Sciences has a beta of -0.856, which suggesting that the stock is 185.551% less volatile than S&P 500. In comparison EyePoint Pharmaceuticals has a beta of 1.455, suggesting its more volatile than the S&P 500 by 45.456%.

Cassava Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences pays -- of its earnings as a dividend. EyePoint Pharmaceuticals pays out -- of its earnings as a dividend.

Cassava Sciences quarterly revenues are --, which are smaller than EyePoint Pharmaceuticals quarterly revenues of $10.5M. Cassava Sciences's net income of -$27.9M is higher than EyePoint Pharmaceuticals's net income of -$29.4M. Notably, Cassava Sciences's price-to-earnings ratio is -- while EyePoint Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences is 2.59x versus 7.90x for EyePoint Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.